Fig. 4
Tumor response to recombinant IL-1α differs between immunodeficient and immunocompetent mouse models. Athymic nu/nu mice (n = 10 [n = 5 male/n = 5 female]) bearing SQ20B tumors (a, c) or BALB/c mice (n = 10 [n = 5 male/n = 5 female]) bearing TUBO-EGFR tumors (b, d) were treated with cetuximab (CTX, 2 mg/kg [8 mg/kg for TUBO-EGFR tumors], twice/week) with or without 0.6 μg human (a, c) or murine (b, d) recombinant IL-1α (rIL-1α) for 2 weeks. IgG and H2O were used as controls. IL-α was given at least half an hour prior to CTX or IgG administration, and again 24 h later totaling 4 doses of CTX and IgG, and 8 doses of IL-1α and H2O. Tumor growth (a, b) and mouse weights (C,D) were measured 3–5 times per week. Tumor growth curves shown were stopped after a mouse in any treatment group reached euthanasia criteria. Error bars = SEM. *: p < 0.05